Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $47 to $80.
Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $47 to $80.